144 related articles for article (PubMed ID: 22681552)
1. Glycoengineering approach to half-life extension of recombinant biotherapeutics.
Chen C; Constantinou A; Chester KA; Vyas B; Canis K; Haslam SM; Dell A; Epenetos AA; Deonarain MP
Bioconjug Chem; 2012 Aug; 23(8):1524-33. PubMed ID: 22681552
[TBL] [Abstract][Full Text] [Related]
2. Site-specific polysialylation of an antitumor single-chain Fv fragment.
Constantinou A; Epenetos AA; Hreczuk-Hirst D; Jain S; Wright M; Chester KA; Deonarain MP
Bioconjug Chem; 2009 May; 20(5):924-31. PubMed ID: 19402707
[TBL] [Abstract][Full Text] [Related]
3. Half-life extension of a single-chain diabody by fusion to domain B of staphylococcal protein A.
Unverdorben F; Färber-Schwarz A; Richter F; Hutt M; Kontermann RE
Protein Eng Des Sel; 2012 Feb; 25(2):81-8. PubMed ID: 22238430
[TBL] [Abstract][Full Text] [Related]
4. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life.
Schlapschy M; Theobald I; Mack H; Schottelius M; Wester HJ; Skerra A
Protein Eng Des Sel; 2007 Jun; 20(6):273-84. PubMed ID: 17595342
[TBL] [Abstract][Full Text] [Related]
5. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells.
Sommaruga S; Lombardi A; Salvadè A; Mazzucchelli S; Corsi F; Galeffi P; Tortora P; Prosperi D
Appl Microbiol Biotechnol; 2011 Aug; 91(3):613-21. PubMed ID: 21538107
[TBL] [Abstract][Full Text] [Related]
6. An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action.
Berger V; Richter F; Zettlitz K; Unverdorben F; Scheurich P; Herrmann A; Pfizenmaier K; Kontermann RE
Protein Eng Des Sel; 2013 Oct; 26(10):581-7. PubMed ID: 24006371
[TBL] [Abstract][Full Text] [Related]
7. Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase.
Kampmeier F; Ribbert M; Nachreiner T; Dembski S; Beaufils F; Brecht A; Barth S
Bioconjug Chem; 2009 May; 20(5):1010-5. PubMed ID: 19388673
[TBL] [Abstract][Full Text] [Related]
8. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
9. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein.
Hopp J; Hornig N; Zettlitz KA; Schwarz A; Fuss N; Müller D; Kontermann RE
Protein Eng Des Sel; 2010 Nov; 23(11):827-34. PubMed ID: 20817756
[TBL] [Abstract][Full Text] [Related]
10. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
11. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
12. [Construction and expression of human anti-HER2 scFv-9R fusion protein and identification of its activity].
Jiang K; Chen R; Wang LF; Ma Q; Meng YL; Yang AG; Ma BA; Qiu XC
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Nov; 27(11):1201-3. PubMed ID: 22078448
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
14. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer.
Vaneycken I; Devoogdt N; Van Gassen N; Vincke C; Xavier C; Wernery U; Muyldermans S; Lahoutte T; Caveliers V
FASEB J; 2011 Jul; 25(7):2433-46. PubMed ID: 21478264
[TBL] [Abstract][Full Text] [Related]
15. Fc engineering: serum half-life modulation through FcRn binding.
Olafsen T
Methods Mol Biol; 2012; 907():537-56. PubMed ID: 22907373
[TBL] [Abstract][Full Text] [Related]
16. Integration of PEGylation and refolding for renaturation of recombinant proteins from insoluble aggregates produced in bacteria--application to a single-chain Fv fragment.
Kumagai I; Asano R; Nakanishi T; Hashikami K; Tanaka S; Badran A; Sanada H; Umetsu M
J Biosci Bioeng; 2010 May; 109(5):447-52. PubMed ID: 20347766
[TBL] [Abstract][Full Text] [Related]
17. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
[TBL] [Abstract][Full Text] [Related]
18. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
19. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by Sortase A-mediated protein ligation.
Madej MP; Coia G; Williams CC; Caine JM; Pearce LA; Attwood R; Bartone NA; Dolezal O; Nisbet RM; Nuttall SD; Adams TE
Biotechnol Bioeng; 2012 Jun; 109(6):1461-70. PubMed ID: 22170409
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
